In Regard to Yadav et al

We have read with great interest the article by Yadav et al (1), which was published in your estemeed journal. The aim of the study was to report results in terms of the feasibility and early toxicity of hypofractionated adjuvant whole breast–chest wall and regional nodal radiation therapy in patients with breast cancer. According to the authors, a two-week hypofractionated radiotherapy [34 Gy/10x (+ boost 10 Gy/5x)] appears to be feasible in patients with breast cancer and was associated with acute and late skin toxicity profiles that are similar to what has been observed during 3 weeks of treatment (35 Gy/15x).

https://ift.tt/2JcCz0Y